Matches in SemOpenAlex for { <https://semopenalex.org/work/W2951532130> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2951532130 abstract "e15160 Background: Pts who receive first line for CRPC are usually treated with 8-10 consecutive courses of D. The pts quality of life (QL) may be worsened and an I administration could limit this effect. E is an old drug showing a synergistic action with D. This study is aimed to compare QL of C and I D and whether E added to D improved its activity, in a 2 × 2 factorial design. Methods: CRPC pts were randomized to: C D 70 mg/m2 IV q 3 wks for 8 courses alone (arm A) or with E 280 mg/TID PO for 5 days starting 1 day prior to D (arm B), or the same treatments given with a 3-month rest period after the first 4 courses (arm C and D, respectively). The primary end points were QL (EORTC QLQ C30 and BPI) of A+B vs C+D and 1-y PFS (according to PCWG2) of A+C vs B+D. Results: 148 CRPC pts were enrolled from 11/06 to 10/10 with 128 pts evaluable at this time. The median age was 69 (range 42-81) and the median baseline PSA was 55.6 (range 0.33-4212). The major hematological toxicities were: anemia G3 (3 pts), neutropenia G3 (4 pts) – G4 (5 pts), febrile neutropenia (5 pts). Comparing C and I, QL outcomes were not statistically different in terms of general QL items. Comparing D and DE, 1-y PFS was superimposable (10% and 13.5%, respectively). The 2-y overall survival was not different between I and C arms 42.5% and 53.7% respectively) and between D and DE arms (42.8% and 53.5% respectively). Conclusions: These preliminary results suggest that I treatment did not produce a QL advantage compared to C treatment, while the addition of E to D did not improve 1-y PFS of CRPC pts." @default.
- W2951532130 created "2019-06-27" @default.
- W2951532130 creator A5001018963 @default.
- W2951532130 creator A5013913173 @default.
- W2951532130 creator A5016392872 @default.
- W2951532130 creator A5018364981 @default.
- W2951532130 creator A5020711568 @default.
- W2951532130 creator A5022699386 @default.
- W2951532130 creator A5024574553 @default.
- W2951532130 creator A5025797878 @default.
- W2951532130 creator A5030122361 @default.
- W2951532130 creator A5031913025 @default.
- W2951532130 creator A5035120623 @default.
- W2951532130 creator A5055092713 @default.
- W2951532130 creator A5073892178 @default.
- W2951532130 creator A5075400298 @default.
- W2951532130 creator A5080212287 @default.
- W2951532130 creator A5082704939 @default.
- W2951532130 date "2012-05-20" @default.
- W2951532130 modified "2023-09-28" @default.
- W2951532130 title "Factorial phase II randomized trial of continuous (C) or intermittent (I) docetaxel (D) with or without estramustine (E) as first-line treatment for castration-resistant prostate cancer (CRPC): Preliminary results of HOPLITE trial." @default.
- W2951532130 doi "https://doi.org/10.1200/jco.2012.30.15_suppl.e15160" @default.
- W2951532130 hasPublicationYear "2012" @default.
- W2951532130 type Work @default.
- W2951532130 sameAs 2951532130 @default.
- W2951532130 citedByCount "0" @default.
- W2951532130 crossrefType "journal-article" @default.
- W2951532130 hasAuthorship W2951532130A5001018963 @default.
- W2951532130 hasAuthorship W2951532130A5013913173 @default.
- W2951532130 hasAuthorship W2951532130A5016392872 @default.
- W2951532130 hasAuthorship W2951532130A5018364981 @default.
- W2951532130 hasAuthorship W2951532130A5020711568 @default.
- W2951532130 hasAuthorship W2951532130A5022699386 @default.
- W2951532130 hasAuthorship W2951532130A5024574553 @default.
- W2951532130 hasAuthorship W2951532130A5025797878 @default.
- W2951532130 hasAuthorship W2951532130A5030122361 @default.
- W2951532130 hasAuthorship W2951532130A5031913025 @default.
- W2951532130 hasAuthorship W2951532130A5035120623 @default.
- W2951532130 hasAuthorship W2951532130A5055092713 @default.
- W2951532130 hasAuthorship W2951532130A5073892178 @default.
- W2951532130 hasAuthorship W2951532130A5075400298 @default.
- W2951532130 hasAuthorship W2951532130A5080212287 @default.
- W2951532130 hasAuthorship W2951532130A5082704939 @default.
- W2951532130 hasConcept C121608353 @default.
- W2951532130 hasConcept C126322002 @default.
- W2951532130 hasConcept C126894567 @default.
- W2951532130 hasConcept C143998085 @default.
- W2951532130 hasConcept C168563851 @default.
- W2951532130 hasConcept C2779256933 @default.
- W2951532130 hasConcept C2780192828 @default.
- W2951532130 hasConcept C2780201970 @default.
- W2951532130 hasConcept C2781190966 @default.
- W2951532130 hasConcept C2994223898 @default.
- W2951532130 hasConcept C71315377 @default.
- W2951532130 hasConcept C71924100 @default.
- W2951532130 hasConceptScore W2951532130C121608353 @default.
- W2951532130 hasConceptScore W2951532130C126322002 @default.
- W2951532130 hasConceptScore W2951532130C126894567 @default.
- W2951532130 hasConceptScore W2951532130C143998085 @default.
- W2951532130 hasConceptScore W2951532130C168563851 @default.
- W2951532130 hasConceptScore W2951532130C2779256933 @default.
- W2951532130 hasConceptScore W2951532130C2780192828 @default.
- W2951532130 hasConceptScore W2951532130C2780201970 @default.
- W2951532130 hasConceptScore W2951532130C2781190966 @default.
- W2951532130 hasConceptScore W2951532130C2994223898 @default.
- W2951532130 hasConceptScore W2951532130C71315377 @default.
- W2951532130 hasConceptScore W2951532130C71924100 @default.
- W2951532130 hasLocation W29515321301 @default.
- W2951532130 hasOpenAccess W2951532130 @default.
- W2951532130 hasPrimaryLocation W29515321301 @default.
- W2951532130 isParatext "false" @default.
- W2951532130 isRetracted "false" @default.
- W2951532130 magId "2951532130" @default.
- W2951532130 workType "article" @default.